Analysts: Payers moving to address MS market as prices rise

Analysts: Payers moving to address MS market as prices rise

The impending payer crackdown of the cost of MS drugs could portend the fate of other specialty drug markets, according to analysts.

PBMs unveil 2017 formularies, retain focus on exclusions

PBMs unveil 2017 formularies, retain focus on exclusions

Express Scripts and CVS Health revealed their formularies with Pfizer's Xeljanz making the jump from excluded to preferred for Express Scripts.

Five things for pharma marketers to know: Tuesday, July 5, 2016

Five things for pharma marketers to know: Tuesday, July 5, 2016

States and insurers are lifting restrictions on HCV drugs; Teva's request to join PhRMA raises eyebrows; Merck partners with GPO

BodenPR helps UnitedHealthcare educate Hispanic seniors about Medicare

BodenPR helps UnitedHealthcare educate Hispanic seniors about Medicare

UnitedHealthcare this month launched a year-long campaign, called Hay Más Adelante.

Five things for pharma marketers to know: Wednesday, May 11, 2016

Five things for pharma marketers to know: Wednesday, May 11, 2016

Cigna signs value contracts for new cholesterol drugs; Yelp partners with ProPublica for hospital reviews; ad-blocking threat to digital publishers intensifies

Amgen takes issue with yet-to-be published multiple-myeloma drug report

Amgen takes issue with yet-to-be published multiple-myeloma drug report

The drugmaker instead suggested using an economic model it developed.

Five things for pharma marketers to know: Friday, March 18, 2016

Five things for pharma marketers to know: Friday, March 18, 2016

OptumRx partners with Walgreens Boots Alliance; Turing's former lawyer said Daraprim price hike was unjustified; the White House names moonshot leader

Five things for pharma marketers to know: Thursday, March 3, 2016

Five things for pharma marketers to know: Thursday, March 3, 2016

Novo's Tresiba gets non-preferred status; Valeant's head of dermatology and gastrointestinal products resigns; Trump plans to allow importation of drugs from abroad

Eli Lilly's diabetes drugs drive sales

Eli Lilly's diabetes drugs drive sales

The pharmaceutical company reported a 2% revenue increase in 2015, and diabetes medication is a key contributor.

Novartis says slow Entresto sales due to limited access

Novartis says slow Entresto sales due to limited access

In many cases, the drug required physicians to request prior authorization.

Five things for pharma marketers to know: Wednesday, December 16, 2015

Five things for pharma marketers to know: Wednesday, December 16, 2015

Britain says Bristol-Myers Squibb's Opdivo is too expensive; Calpers reports 32% boost in specialty drug spending; NIH is funding fewer clinical trials

Five things for pharma marketers to know: Friday, December 11, 2015

Five things for pharma marketers to know: Friday, December 11, 2015

UnitedHealth gives Praluent preferred status on its formularies; Stat News examines the first DTC drug ad; Britain to cover Entresto

Drugmakers explore response to pricing debate

Drugmakers explore response to pricing debate

Some pharma companies are taking steps to address concerns about the high prices of drugs at a time when Democratic lawmakers are urging price controls.

Five things for pharma marketers to know: Monday, November 9, 2015

Five things for pharma marketers to know: Monday, November 9, 2015

More patients may be eligible for new PCSK9 inhibitors; Collegium's painkiller may receive FDA approval; MannKind's Afrezza reports slow sales

Five things for pharma marketers to know: Friday, November 6, 2015

Five things for pharma marketers to know: Friday, November 6, 2015

Obama administration tells states they cannot restrict hep-C drugs; AstraZeneca says it will acquire ZS Pharma: Allergan CEO says drug discovery is too risky